source
- Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune diseasePfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
- FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefitThe U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…